Psychiatric and physical outcomes of long-term use of lithium in older adults with bipolar disorder and major depressive disorder: A cross-sectional multicenter study.
Aged
Aging
/ drug effects
Antidepressive Agents
/ adverse effects
Antipsychotic Agents
/ adverse effects
Benzodiazepines
/ therapeutic use
Bipolar Disorder
/ drug therapy
Comorbidity
Cross-Sectional Studies
Depression
Depressive Disorder, Major
/ drug therapy
Depressive Disorder, Treatment-Resistant
/ drug therapy
Female
Hospitalization
/ statistics & numerical data
Humans
Lithium Compounds
/ adverse effects
Male
Middle Aged
Bipolar disorder
Effectiveness
Lithium
Long-term
Major depressive disorder
Older adults
Tolerability
Journal
Journal of affective disorders
ISSN: 1573-2517
Titre abrégé: J Affect Disord
Pays: Netherlands
ID NLM: 7906073
Informations de publication
Date de publication:
01 12 2019
01 12 2019
Historique:
received:
15
03
2019
revised:
11
07
2019
accepted:
18
08
2019
pubmed:
26
8
2019
medline:
14
7
2020
entrez:
26
8
2019
Statut:
ppublish
Résumé
Although lithium is widely used in current practice to treat bipolar disorder (BD) and treatment-resistant major depressive disorder (MDD) among older adults, little is known about its efficacy and tolerability in this population, which is generally excluded from randomized clinical trials. The objective of this study was to evaluate the efficacy and tolerability of long-term use of lithium among older adults with BD and MDD. Data from the Cohort of individuals with Schizophrenia and mood disorders Aged 55 years or more (CSA) were used. Two groups of patients with BD and MDD were compared: those who were currently receiving lithium versus those who were not. The effects of lithium on psychiatric (i.e., depressive symptoms severity, perceived clinical severity, rates of psychiatric admissions in the past-year), geriatric (overall and cognitive functioning) and physical outcomes (i.e., rates of non-psychiatric medical comorbidities and general hospital admissions in the past-year) were evaluated. All analyses were adjusted for age, sex, duration of disorder, diagnosis, smoking status, alcohol use, and use of antipsychotics, antiepileptics or antidepressants. Among the 281 older participants with BD or MDD, 15.7% were taking lithium for a mean duration of 12.5(SD = 11.6) years. Lithium use was associated with lower intensity of depressive symptoms, reduced perceived clinical global severity and lower benzodiazepine use (all p < 0.05), without being linked to greater rates of medical comorbidities, except for hypothyroidism. Data were cross-sectional and data on lifetime history of psychotropic medications was not assessed. Our results suggest that long-term lithium use may be efficient and relatively well-tolerated in older adults with BD or treatment-resistant MDD.
Identifiants
pubmed: 31446382
pii: S0165-0327(19)30675-5
doi: 10.1016/j.jad.2019.08.056
pii:
doi:
Substances chimiques
Antidepressive Agents
0
Antipsychotic Agents
0
Lithium Compounds
0
Benzodiazepines
12794-10-4
Types de publication
Clinical Trial
Journal Article
Multicenter Study
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
210-217Investigateurs
J Adès
(J)
C Alezrah
(C)
I Amado
(I)
G Amar
(G)
O Andréi
(O)
D Arbault
(D)
G Archambault
(G)
G Aurifeuille
(G)
S Barrière
(S)
C Béra-Potelle
(C)
Y Blumenstock
(Y)
H Bardou
(H)
M Bareil-Guérin
(M)
P Barrau
(P)
C Barrouillet
(C)
E Baup
(E)
N Bazin
(N)
B Beaufils
(B)
J Ben Ayed
(J)
M Benoit
(M)
K Benyacoub
(K)
T Bichet
(T)
F Blanadet
(F)
O Blanc
(O)
J Blanc-Comiti
(J)
D Boussiron
(D)
A M Bouysse
(AM)
A Brochard
(A)
O Brochart
(O)
B Bucheron
(B)
M Cabot
(M)
V Camus
(V)
J M Chabannes
(JM)
V Charlot
(V)
T Charpeaud
(T)
C Clad-Mor
(C)
C Combes
(C)
M Comisu
(M)
B Cordier
(B)
F Costi
(F)
J P Courcelles
(JP)
M Creixell
(M)
H Cuche
(H)
C Cuervo-Lombard
(C)
A Dammak
(A)
D Da Rin
(D)
J B Denis
(JB)
H Denizot
(H)
A Deperthuis
(A)
E Diers
(E)
S Dirami
(S)
D Donneau
(D)
P Dreano
(P)
C Dubertret
(C)
E Duprat
(E)
D Duthoit
(D)
C Fernandez
(C)
P Fonfrede
(P)
N Freitas
(N)
P Gasnier
(P)
J Gauillard
(J)
F Getten
(F)
F Gierski
(F)
F Godart
(F)
R Gourevitch
(R)
A Grassin Delyle
(A)
J Gremion
(J)
H Gres
(H)
V Griner
(V)
C Guerin-Langlois
(C)
C Guggiari
(C)
O Guillin
(O)
H Hadaoui
(H)
E Haffen
(E)
C Hanon
(C)
S Haouzir
(S)
C Hazif-Thomas
(C)
A Heron
(A)
B Hubsch
(B)
I Jalenques
(I)
D Januel
(D)
A Kaladjian
(A)
J F Karnycheff
(JF)
O Kebir
(O)
M O Krebs
(MO)
C Lajugie
(C)
M Leboyer
(M)
P Legrand
(P)
M Lejoyeux
(M)
V Lemaire
(V)
E Leroy
(E)
D Levy-Chavagnat
(D)
A Leydier
(A)
C Liling
(C)
P M Llorca
(PM)
P Loeffel
(P)
P Louville
(P)
S Lucas Navarro
(S)
N Mages
(N)
M Mahi
(M)
O Maillet
(O)
A Manetti
(A)
C Martelli
(C)
P Martin
(P)
M Masson
(M)
I Maurs-Ferrer
(I)
J Mauvieux
(J)
S Mazmanian
(S)
E Mechin
(E)
L Mekaoui
(L)
M Meniai
(M)
A Metton
(A)
A Mihoubi
(A)
M Miron
(M)
G Mora
(G)
V Niro Adès
(V)
P Nubukpo
(P)
C Omnes
(C)
S Papin
(S)
P Paris
(P)
C Passerieux
(C)
J Pellerin
(J)
J Perlbarg
(J)
S Perron
(S)
A Petit
(A)
F Petitjean
(F)
C Portefaix
(C)
D Pringuey
(D)
A Radtchenko
(A)
H Rahiou
(H)
D Raucher-Chéné
(D)
A Rauzy
(A)
L Reinheimer
(L)
M Renard
(M)
M René
(M)
C E Rengade
(CE)
P Reynaud
(P)
D Robin
(D)
C Rodrigues
(C)
A Rollet
(A)
F Rondepierre
(F)
B Rousselot
(B)
S Rubingher
(S)
G Saba
(G)
J P Salvarelli
(JP)
J C Samuelian
(JC)
C Scemama-Ammar
(C)
F Schurhoff
(F)
J P Schuster
(JP)
D Sechter
(D)
B Segalas
(B)
T Seguret
(T)
A S Seigneurie
(AS)
A Semmak
(A)
F Slama
(F)
S Taisne
(S)
M Taleb
(M)
J L Terra
(JL)
D Thefenne
(D)
E Tran
(E)
R Tourtauchaux
(R)
M N Vacheron
(MN)
P Vandel
(P)
V Vanhoucke
(V)
E Venet
(E)
H Verdoux
(H)
A Viala
(A)
G Vidon
(G)
M Vitre
(M)
J L Vurpas
(JL)
C Wagermez
(C)
M Walter
(M)
L Yon
(L)
X Zendjidjian
(X)
Informations de copyright
Copyright © 2019 Elsevier B.V. All rights reserved.